Eptifibatide Injection 20 mg Per 10 mL Single-Dose Vial 10 mL (RX)

#1 Glycoprotein IIb/IIIa Inhibitor for Acute Coronary Syndrome (ACS), PCI, and Cardiac Intervention

Eptifibatide Injection 20 mg per 10 mL, Single-Dose Vial (10 mL) is a best-in-class, hospital-grade glycoprotein IIb/IIIa inhibitor designed for rapid and effective antiplatelet therapy in acute coronary syndrome (ACS), unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and percutaneous coronary intervention (PCI) procedures. Trusted by leading cardiology teams and cath labs, Eptifibatide delivers precise, targeted platelet inhibition, reducing the risk of thrombotic complications during high-risk cardiac events and interventions.

Uses

• Acute Coronary Syndrome (ACS): Key agent in managing unstable angina and NSTEMI to prevent cardiac ischemia, infarct progression, and death.
• Percutaneous Coronary Intervention (PCI): Gold standard for reducing periprocedural thrombotic complications during stent placement or balloon angioplasty.
• Adjunct to Heparin & Aspirin: Works synergistically with unfractionated heparin and aspirin for optimal platelet inhibition and thrombus prevention.
• High-Risk Cardiac Patients: Use in patients with diabetes, multiple vessel disease, renal impairment, or high clot burden for best-in-class ischemic event reduction.

Features & Top Benefits

• Powerful Antiplatelet Activity: Directly inhibits platelet aggregation by blocking glycoprotein IIb/IIIa receptors, the final common pathway for platelet clumping and clot formation.
• Rapid Onset & Predictable Action: Ideal for urgent and emergent scenarios in the cath lab, ICU, OR, and emergency department.
• Flexible Dosing: Each single-dose 10 mL vial with 20 mg eptifibatide supports accurate, weight-based IV bolus and infusion protocols.
• Enhances PCI Outcomes: Proven to reduce major adverse cardiac events (MACE) such as MI, repeat revascularization, and death during and after PCI.
• JCAHO and AHA Guideline-Compliant: Meets critical care and cardiac intervention standards for antiplatelet therapy in ACS management.
• Single-Dose, Sterile Packaging: Lowers the risk of contamination and medication errors—ideal for hospital, cath lab, emergency, and bedside administration.

Safety Information & Side Effects

Eptifibatide Injection is a potent IV antiplatelet agent and should be administered under experienced medical supervision with appropriate monitoring.

Common Side Effects:

• Mild to moderate bleeding (puncture sites, gums, GI tract, nose)
• Thrombocytopenia
• Minor headache, nausea

Serious Side Effects:

• Severe bleeding (intracranial, retroperitoneal, GI, hematuria)
• Anaphylaxis or hypersensitivity reactions (rare)
• Severe thrombocytopenia (requires platelet monitoring)

Caution: Contraindicated in active bleeding, recent stroke, severe uncontrolled hypertension, major surgery within 6 weeks, history of bleeding diathesis, or severe renal impairment (dose adjustment required).

Why Choose Eptifibatide Injection 20 mg/10 mL, Single-Dose Vial?

• Hospital-Approved Standard: Trusted by cath labs, cardiologists, emergency physicians, and critical care teams worldwide.
• Optimized, Ready-to-Use Dosing: Single-dose vials streamline workflow and enable fast-response therapy when every second counts.
• Highest Efficacy in ACS/PCI: Reduces recurrent MI, urgent repeat revascularization, and mortality in high-risk acute coronary syndrome and PCI patients.
• Safe, Predictable Action: Short plasma half-life enables prompt reversal/cessation if bleeding occurs.

Order Eptifibatide Injection 20 mg/10 mL, Single-Dose Vial Today!

Keep your cath lab, ER, and cardiac care units ready for every acute event with the #1 antiplatelet intervention for ACS, PCI, and state-of-the-art cardiac protection. Equip your hospital or institution with Eptifibatide Injection for confident, guideline-based, and life-saving therapy today!